All In Biotech

Drug Trial Radar · NCT05271604

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Dec 13, 2022

Primary completion

Sep 22, 2025

Study completion Sep 22, 2025

Sponsor

Lead sponsor
BioAtla, Inc.Industry
Sponsor type
Industry
First posted
Mar 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Conditions

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Cancer
  • Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions

  • Ozuriftamab VedotinBiological

    Conditionally active biologic anti-ROR2 antibody drug conjugate

  • PembrolizumabBiological

    PD-1 inhibitor

  • Evalstotug (BA3071)Biological

    Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody

  • CetuximabBiological

    Epidermal growth factor receptor (EGFR) antagonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) per RECIST v1.1Time frame: Up to 24 months
  2. Incidence of Adverse Events or Serious Adverse Events as assessed by CTCAE v5Time frame: Up to 24 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Christiana Care Helen Graham Cancer Center

    Newark, Delaware

  • Northwestern University

    Chicago, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • Washington University Medical Siteman Cancer Center

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.